Moleculin Biotech
MBRX
18 hedge funds and large institutions have $2.3M invested in Moleculin Biotech in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
24% more capital invested
Capital invested by funds: $1.85M → $2.3M (+$449K)
6% more funds holding
Funds holding: 17 → 18 (+1)
1% more ownership
Funds ownership: 3.99% → 4.98% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$209K |
| 2 |
BlackRock
New York
|
+$90.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$73.7K |
| 4 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$53.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$24K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$9K |
| 3 |
ACS
Archford Capital Strategies
Swansea,
Illinois
|
-$6K |
MBRX Hedge Fund Activity: Q2 2018 in Review
18 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2018, worth a combined $2.3M — up 24% from $1.85M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MBRX positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $209K. The largest seller was Virtu Financial, exiting entirely with an estimated $24K sold.
- 18 institutional investors held Moleculin Biotech (MBRX) as of Q2 2018, up from 17 in Q1 2018.
- Funds reported $2.3M of Moleculin Biotech stock for Q2 2018, up 24% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q2 2018 and 3 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q2 2018 was Vanguard Group, an estimated $209K added.
- The largest Moleculin Biotech seller in Q2 2018 was Virtu Financial, an estimated $24K sold.
Based on aggregated 13F filings for Q2 2018.